Plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma [ID1081]
In development [GID-TA10171] Expected publication date: TBC
Search results
665 results
-
-
Peramivir for treating influenza [ID828]
In development [GID-TA10155] Expected publication date: TBC
-
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
In development [GID-TA10177] Expected publication date: TBC
-
Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]
In development [GID-TA10159] Expected publication date: TBC
-
Lenalidomide for untreated follicular lymphoma ID1245
In development [GID-TA10308] Expected publication date: TBC
-
Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467
In development [GID-TA10353] Expected publication date: TBC
-
Constipation (opioid induced) - methylnaltrexone bromide [ID700]
In development [GID-TA10003] Expected publication date: TBC
-
Leukaemia (chronic lymphocytic) - idelalisib (with ofatumumab) [ID817]
In development [GID-TA10008] Expected publication date: TBC
-
Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]
In development [GID-TA10236] Expected publication date: TBC
-
Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]
In development [GID-TA10028] Expected publication date: TBC
-
Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab ID1487
In development [GID-TA10437] Expected publication date: TBC
-
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997
In development [GID-TA10382] Expected publication date: TBC
-
Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]
In development [GID-TA10338] Expected publication date: TBC
-
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
In development [GID-TA10151] Expected publication date: TBC
-
Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]
In development [GID-TA10154] Expected publication date: TBC
-
Renal cell carcinoma - sunitinib [ID1076]
In development [GID-TA10166] Expected publication date: TBC
-
Osteoarthritis - diacerein [ID332]
In development [GID-TAG250] Expected publication date: TBC
-
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172
In development [GID-TA10394] Expected publication date: TBC
-
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
In development [GID-TA10404] Expected publication date: TBC
-
Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]
In development [GID-TAG431] Expected publication date: TBC
-
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]
In development [GID-TAG425] Expected publication date: TBC
-
Pulmonary arterial hypertension (adults) - drugs [ID12]
In development [GID-TAG382] Expected publication date: TBC
-
Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]
In development [GID-TAG444] Expected publication date: TBC
-
Breast cancer - intensity modulated radiotherapy [ID16]
In development [GID-TAG390] Expected publication date: TBC
-
Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)
In development [GID-TA10337] Expected publication date: 19 February 2020
-
Pacritinib for treating myelofibrosis [ID880]
In development [GID-TA10133] Expected publication date: TBC
-
LJ TEST
In development [GID-TA10462] Expected publication date: TBC
-
Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies ID1288
In development [GID-TA10212] Expected publication date: TBC
-
Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]
In development [GID-TA10271] Expected publication date: TBC
-
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]
In development [GID-TA10575] Expected publication date: TBC
-
Eculizumab for treating relapsing neuromyelitis optica [ID1271]
In development [GID-TA10469] Expected publication date: 02 September 2020
-
Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179
In development [GID-TA10450] Expected publication date: TBC
-
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]
In development [GID-TA10635] Expected publication date: TBC
-
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
In development [GID-TA10254] Expected publication date: TBC
-
Luspatercept for treating beta-thalassaemia ID1554
In development [GID-TA10506] Expected publication date: TBC
-
Kidney transplantation (rejection) - everolimus [ID117]
In development [GID-TAG241] Expected publication date: TBC
-
Eltrombopag for untreated severe aplastic anaemia ID1198
In development [GID-TA10284] Expected publication date: TBC
-
Pembrolizumab with epacadostat for untreated malignant melanoma ID1423
In development [GID-TA10330] Expected publication date: TBC
-
Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228
In development [GID-TA10203] Expected publication date: TBC
-
Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]
In development [GID-TA10149] Expected publication date: TBC
-
Bevacizumab for untreated malignant pleural mesothelioma (ID1183)
In development [GID-TA10197] Expected publication date: TBC
-
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
In development [GID-TAG321] Expected publication date: TBC
-
Leukaemia (chronic lymphocytic, relapsed) - ofatumumab (maintenance) [ID732]
In development [GID-TAG482] Expected publication date: TBC
-
Vemurafenib for treating resected BRAF V600 mutation-positive melanoma ID1250
In development [GID-TA10213] Expected publication date: TBC
-
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]
In development [GID-TAG507] Expected publication date: TBC
-
Pembrolizumab for previously treated multiple myeloma (ID1139)
In development [GID-TA10193] Expected publication date: TBC
-
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
In development [GID-TAG511] Expected publication date: TBC
-
Lymphoma (mantle cell, relapsed, refractory) - lenalidomide [ID739]
In development [GID-TAG508] Expected publication date: TBC
-
Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]
In development [GID-TA10018] Expected publication date: TBC
-
Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]
In development [GID-TA10033] Expected publication date: TBC